ADRB3 and obesity disorder: In humans, the anti-obesity and metabolic efficacy of the β3-adrenergic agonist CL316243 is limited for multiple reasons, such as low efficacy at the human β3AR, low β3AR expression levels, a limited amount of brown fat and cardiovascular side-effects.